证券代码：524293 证券简称：25 国证 K1 国信证券股份有限公司 2025 年面向专业投资者公开发行 科技创新公司债券（第一期）票面利率公告 发行人及全体董事、监事、高级管理人员保证本公告内容真实、准确和完 整，并对公告中的虚假记载、误导性陈述或者重大遗漏承担责任。 国信证券股份有限公司（以下简称"公司"或"发行人"）向专业投资者公开 发行面值总额不超过 200 亿元公司债券已获得中国证券监督管理委员会证监许 可[2024]1722 号文注册同意。 国信证券股份有限公司 2025 年面向专业投资者公开发行科技创新公司债券 （第一期）（以下简称"本期债券"）发行规模不超过 10 亿元（含 10 亿元）。本 期债券期限为 3 年。 2025 年 6 月 4 日，发行人和主承销商在网下向专业机构投资者进行了票面 利率询价，本期债券利率询价区间为 1.30%-2.30%。根据网下向专业机构投资者 询价结果，经发行人和主承销商按照有关规定协商一致，最终确定本期债券票面 利率为 1.82%。 2 3/4 （本页无正文，为《国信证券股份有限公司 2025 年面向专业投资者公开发行科 技创新公司债券（第一期）票面利率 ...

关于延长国信证券股份有限公司 2025 年面向专业投资者 公开发行科技创新公司债券（第一期）簿记建档时间的公告 国信证券股份有限公司（以下简称"公司"或"发行人"）向专业投资者公开 发行面值总额不超过 200 亿元公司债券已获得中国证券监督管理委员会证监许 可[2024]1722 号文注册同意。 根据《国信证券股份有限公司 2025 年面向专业投资者公开发行科技创新公 司债券（第一期）发行公告》，发行人及簿记管理人原定于 2025 年 6 月 4 日（T-1 日）15:00 到 18:00 以簿记建档的方式向网下投资者进行利率询价，并根据簿记 建档结果确定本期债券的最终票面利率。 1 （本页无正文，为《关于延长国信证券股份有限公司 2025 年面向专业投资者公 开发行科技创新公司债券（第一期）簿记建档时间的公告》之盖章页) 布限公司 2025年 4 日 2 （本页无正文，为《关于延长国信证券股份有限公司 2025 年面向专业投资者公 开发行科技创新公司债券（第一期）簿记建档时间的公告》之盖章页） 中国钱 球券股份有限 2025年 6 月 4 日 因簿记建档当日市场变化较为剧烈，经全体簿记参与人协商一致，现将本 ...

Group 1 - The announcement states that from June 4, 2025, Guoxin Jiali Fund will begin selling certain funds managed by the company [1][2] - The applicable fund range is subject to compliance with the fund contract, prospectus, and related business announcements [4] - Investors can consult details through various channels, including the websites and customer service numbers of both Guoxin Jiali Fund and the company [5][6] Group 2 - The company has signed sales agreements with multiple securities firms and fund sales companies, which will also start selling its funds from June 4, 2025 [2][3] - A comprehensive list of sales institutions includes major securities firms and fund sales companies, indicating a broad distribution network [3][10] - The announcement emphasizes that the specific dates, processes, and fee discount activities for fund sales will be determined by the sales institutions [4]

Group 1 - The core viewpoint is that domestic innovative drugs are increasingly gaining global value, with a trend of going overseas for development [1][2] - The ASCO annual meeting is highlighted as a significant platform for showcasing high-quality research results of domestic innovative drugs, with several promising drug candidates expected to present data [1] - Companies such as Innovent Biologics, Kelun-Biotech, and others are mentioned as having innovative drugs with potential for first-in-class or best-in-class status [1] Group 2 - The report indicates that the collaboration between Innovent Biologics and Pfizer for the PD-1xVEGF bispecific antibody 707, with an upfront payment of $1.25 billion, sets a new record for domestic innovative drugs [2] - There is a noted increase in the number and value of licensing agreements for domestic innovative drugs since the beginning of the year [2] - The release of clinical data is crucial for determining the drug development potential and subsequent global commercialization of these innovative drugs [2]

国信证券股份有限公司 GUOSEN SECURITIES CO.,LTD. 住所:深圳市罗湖区红岭中路 1012 号国信证券大厦十六层至二十六层 国信证券股份有限公司 2025 年面向专业投资者公开发行科技创新公司债券 (第一期)募集说明书 | 注册会额 | 200 亿元 | | --- | --- | | 本期发行规模 | 不超寸 10 亿元 | | 发行人 | 国信证券股份有 | | 主承销商 | 中国银河证券股份有限公 ロ 长城证券股份有限公司 | | 受托管理人 | 中国银河证券股份有限公司 | | 增信措施情况 | 本期债券无增信 | | 信用评级结果 | 发行人主体长期信用等级 AAA,本期债券信用等级 AAA | | 信用评级机构 | 中诚信国际信用评级有限责任公司 | 牵头主承销商/簿记管理人/受托管理人 国银河证券股份有限公司 AXY SECURITIES CO., LTD 住所:北京市丰台区西营街 8 号院 1 号楼 7 至 18 层 101 联席主承销商 秦股份有限公司 住所:深圳市福田区福田街道金田路 2026 号能源大厦南塔楼 10-19 层 签署日期:2025年5月 国信证券股份有 ...

国信证券股份有限公司 2025 年面向专业投资者公开发行科技创新 公司债券（第一期） 发行公告 发行人 牵头主承销商、债券受托管理人 住所：北京市丰台区西营街 8 号院 1 号楼 7 至 18 层 101 联席主承销商 住所：深圳市福田区福田街道金田路 2026 号能源大厦南塔楼 10-19 层 签署时间：二〇二五年五月 本公司及其董事、监事、高级管理人员保证公告内容真实、准确和完整，并对公告 中的虚假记载、误导性陈述或者重大遗漏承担责任。 重要事项提示 1．国信证券股份有限公司（以下简称"发行人"或"公司"）已于 2024 年 11 月 29 日 获得中国证券监督管理委员会证监许可[2024]1722 号文，可向专业投资者公开发行面值 总额不超过 200 亿元的公司债券（以下简称"本次债券"）。 发行人本次债券采取分期发行的方式，"国信证券股份有限公司 2025 年面向专业投 资者公开发行科技创新公司债券（第一期）"（以下简称"本期债券"）为本次债券项下 第五期，发行规模为不超过人民币 10 亿元（含 10 亿元），债券简称"25 国证 K1"。 2．本期债券每张面值为 100 元，发行数量不超过 1,00 ...

国信证券股份有限公司 2025 年面向专业投资者公开发行科技 创新公司债券（第一期） 信用评级报告 编号：CCXI-20251418D-01 国信证券股份有限公司 2025 年面向专业投资者公开发行科技创新公司债券 （第一期）信用评级报告 声 明 跟踪评级安排 中诚信国际信用评级有限责任公司 2025 年 5 月 22 日 * [14] M. C. 本次评级为委托评级，中诚信国际及其评估人员与评级委托方、评级对象不存在任何其他影响本次评级行为独立、 客观、公正的关联关系。 本次评级依据评级对象提供或已经正式对外公布的信息，以及其他根据监管规定收集的信息，中诚信国际按照相关 性、及时性、可靠性的原则对评级信息进行审慎分析，但中诚信国际对于相关信息的合法性、真实性、完整性、准 确性不作任何保证。 中诚信国际及项目人员履行了尽职调查和诚信义务，有充分理由保证本次评级遵循了真实、客观、公正的原则。 评级报告的评级结论是中诚信国际依据合理的内部信用评级标准和方法、评级程序做出的独立判断，未受评级委托 方、评级对象和其他第三方的干预和影响。 本评级报告对评级对象信用状况的任何表述和判断仅作为相关决策参考之用，并不意味着中 ...

国信证券股份有限公司2024年面向专业投资者公开发行 公司债券更名公告 2024 年 11 月 29 日，中国证券监督管理委员会以证监许可[2024]1722 号文 同意国信证券股份有限公司面向专业投资者公开发行公司债券的注册。 由于债券跨年及分期发行，按照公司债券命名惯例，征得主管部门同意，本 期债券名称由"国信证券股份有限公司 2024 年面向专业投资者公开发行公司债 券"变更为"国信证券股份有限公司 2025 年面向专业投资者公开发行科技创新公 司债券（第一期）"，债券简称"25 国证 K1"。 本期债券名称更变不改变原签订的与本期公司债券发行相关的法律文件效 力，原签署的法律文件对更名后的公司债券继续具有法律效力。前述法律文件包 括但不限于：《国信证券股份有限公司 2024 年面向专业投资者公开发行公司债券 之受托管理协议》《国信证券股份有限公司 2024 年面向专业投资者公开发行公司 债券债券持有人会议规则》。 特此说明。 （以下无正文） 1 （此页无正文，为《国信证券股份有限公司 2024 年面向专业投资者公开发行公 司债券更名公告》之盖章页 ) 限公司 国信 vv日 700 3/4 （此页无正文 ...

Group 1: US Market Insights - The core inflation in the US is expected to rise rapidly to 3.8% in Q3, primarily driven by tariffs increasing commodity prices, which suggests that current market expectations of 3.2-3.3% are overly conservative [2] - The anticipated rise in inflation is likely to lead to significant volatility in both the US stock and bond markets, prompting investors to prepare for uncertainty [2] Group 2: A-Share Market Dynamics - A-share market has shifted from sentiment-driven to performance-driven logic, with analysts revising earnings forecasts for various indices, particularly downgrading the Sci-Tech 50 while upgrading sectors like dividends, CSI 500, Shenzhen Component, and CSI 1000 [3] - The correlation between performance, low valuations, and stock prices indicates a transition in the A-share market towards earnings-driven investment strategies [3] Group 3: Hong Kong Market Outlook - The Hong Kong market is supported by continuous earnings upgrades, increasing southbound capital inflows, and a weakening US dollar index, which are all positive indicators for long-term strength [4] - The current recommendation for the Hong Kong market is to hold positions, with no further accumulation above 22,500 points [4] Group 4: Sector Recommendations - In the cloud computing sector, leading companies Tencent and Alibaba have shown strong performance in Q1, with competitive valuations and high liquidity [5] - The new consumption sector is characterized by a large young fan base and strong global expansion potential, while the pharmaceutical sector has shown significant earnings upgrades [5] - Dividend stocks, including operators, banks, and public utilities, are seen as stable performers that can effectively counter uncertainty [5] - The IPO market in Hong Kong has been impressive, with new stocks exceeding 30 billion market capitalization showing a median increase of 128% this year, suggesting opportunities in this area [5] - A focus on stocks with upgraded earnings forecasts is recommended, as the performance of the Hong Kong market is closely tied to earnings strength [5]

Fund Overview - The fund is named "Guotou Ruijin CSI All Share Public Utilities Index Fund" and is classified as an equity fund [16] - The fund operates as a contractual open-end fund [16] - The initial value of each fund share is set at 1.00 RMB [18] Fund Management and Custody - The fund is managed by Guotou Ruijin Fund Management Co., Ltd. and the custodian is China Galaxy Securities Co., Ltd. [44] Fund Offering Details - The fund's initial fundraising cap is set at 2 billion RMB, excluding interest accrued during the fundraising period [20] - The fundraising period is from June 16, 2025, to June 25, 2025 [22] - The fund is open to various investors, including individual and institutional investors, as well as qualified foreign investors [19] Subscription Classes - The fund offers two classes of shares: Class A shares, which charge a subscription fee, and Class C shares, which do not charge a subscription fee [16][26] - The subscription codes for Class A and Class C shares are 024192 and 024193, respectively [17] Subscription Process - Investors can subscribe multiple times during the fundraising period, with a minimum subscription amount of 1 RMB [11][30] - Subscription applications may be partially confirmed if the total subscription amount exceeds the fundraising cap [20][21] Interest and Share Calculation - Interest accrued on subscription funds during the fundraising period will be converted into fund shares for the holders [42] - The calculation of subscription shares is based on the net subscription amount plus interest earned [28][30] Regulatory Compliance - The fund is subject to regulatory approval and must meet specific conditions to ensure the contract's effectiveness [43] - The fund's contract will automatically terminate if the asset size falls below 20 million RMB after three years [13] Sales Channels - The fund will be sold through various sales institutions, including direct sales by Guotou Ruijin Fund Management Co., Ltd. and other securities firms [24] - Investors are encouraged to consult the sales institutions for detailed procedures and requirements [5]